Most recently, Francomano served as Senior Vice President, Global Head of Commercial and Medical Affairs for Stemline (STML). Prior to this, Francomano garnered extensive oncology experience operating in global roles for Baxalta, Pfizer (PFE) and GlaxoSmithKline (GSK), where he developed strategies for assets in clinical development from Phase I through Phase IV.

In an interview on CNBC's Mad Money, Boot Barn CEO Jim Conroy said: Most of our product is still for functional use, but we've picked up in the fashionable space... We have diversified quite a bit... We are now in 33 states... We think we can double the store count... Our exclusive brands now make up about 25% of sales... We've been able to mitigate the impact of the China tariffs.

This is the lowest level of holdings since September 19th.

Quorum Health Corporation announced that it was notified on December 3, 2019 by the New York Stock Exchange that it was not in compliance with the NYSE's continued listing standards as a result of the average closing price of the company's common stock being less than $1.00 per share over a consecutive 30 trading-day period. As set forth in the December Notice, as of December 3, 2019, the 30 trading-day average closing share price of the company's common stock was 90c. In accordance with the NYSE rules, the company has a period of six months following the receipt of the December Notice to regain compliance with the minimum share price requirement. The company plans to notify the NYSE within 10 business days of its intent to cure the deficiency. The company can regain compliance with the minimum share price requirement at any time during the six month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on such date.

The record date for the special distribution is December 17, and the payment date for the distribution is December 26. This is a part of the ongoing capital allocation review being conducted by the Board.

Alector reported safety and biomarker data from the single ascending dose phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer's disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer's Disease meeting being held December 4-6 in San Diego, California. The AL002 presentation at CTAD showcases the first data in humans showing that a TREM2 activating antibody engages its target and demonstrates downstream activity in the CNS. Robert Paul, M.D., Ph.D., chief medical officer of Alector, presented an abstract entitled, A Phase 1 Study of AL002 in Healthy Volunteers and Patients With Mild-To-Moderate Alzheimer's Disease during an oral communications session. The INVOKE clinical study is a first-in-human study in healthy adults and in patients with mild to moderate Alzheimer's disease, designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of AL002. The data reported today are from the study's SAD phase in 56 healthy adults, who were enrolled into nine escalating dose cohorts. Summary of the clinical data of the SAD portion of the Phase 1 INVOKE clinical study presented at CTAD: 56 healthy volunteers were treated with nine escalating doses of AL002; AL002 was found to be generally safe and well-tolerated; AL002 reduced cerebrospinal fluid soluble TREM2 in a dose-dependent manner, demonstrating proof-of-target engagement in the brain; AL002 elevated a biomarker for microglia activity in the CSF, indicating proof-of-mechanism; the Phase 1b portion of the study in Alzheimer's disease patients is on-going. Alector expects to initiate the AL002 Phase 2, proof-of-concept study in 2020. "Loss of TREM2 activity has been shown through human genetics to be one of the major risk factors of developing Alzheimer's disease," said Robert Paul, M.D., Ph.D., chief medical officer of Alector. "AL002 is the first TREM2 agonistic antibody in clinical development for Alzheimer's disease, and we are pleased to see safety and tolerability in healthy volunteers and that AL002 is showing proof-of-target engagement and proof-of-mechanism at this early stage in development. These results together will help guide our dose selection for the Phase 2 study in Alzheimer's patients."